Management of adrenal cancer: A 2013 update

Journal of Endocrinological Investigation

Volumn 37, Issue 3, 2014, Pages 207-217

  Terzolo, M ^a   Daffara, F ^a   Ardito, A ^a   Zaggia, B ^a   Basile, V ^a   Ferrari, L ^b   Berruti, A ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adjuvant treatment; Adrenal cancer; Adrenocortical carcinoma; Chemotherapy; Cisplatin; Mitotane; Overall survival; Recurrence free survival

Indexed keywords

CAPECITABINE; CISPLATIN; CISPLATIN DERIVATIVE; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FIGITUMUMAB; FLUOROURACIL; GEMCITABINE; GLUCOCORTICOID; LINSITINIB; MITOTANE; OSI 906301; UNCLASSIFIED DRUG;

ADDISON DISEASE; ADRENAL CANCER; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ATTENTION DEFICIT DISORDER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CORTICOSTEROID THERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; HYPOTHYROIDISM; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MEMORY DISORDER; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; OLIGOMENORRHEA; OVARY CYST; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SYSTEMIC THERAPY; VAGINA BLEEDING; ADRENAL GLAND NEOPLASMS; CANCER STAGING; DISEASE MANAGEMENT; PROGNOSIS; TIME;

ADRENAL GLAND NEOPLASMS; DISEASE MANAGEMENT; HUMANS; NEOPLASM STAGING; PROGNOSIS; TIME FACTORS;

EID: 84900548631     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-013-0049-2     Document Type: Review

References (79)

1. Terzolo M, Ardito A, Zaggia B et al (2012) Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine 42(3):521-525
2. Fassnacht M, Libé R, Kroiss M et al (2011) Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 7:323-335
3. Bourdeau I, Mackenzie-Feder J, Lacroix A (2013) Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes 20:192-197
4. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30:872-878
5. Kerkhofs TM, Verhoeven RH, Van der Zwan JM et al (2013) Adrenocortical carcinoma: a population based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49(11):2579-2586
6. Berruti A, Baudin E, Gelderblom H et al (2012) Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 23(Suppl 7):VII131-VII138
7. Lombardi CP, Raffaelli M, Boniardi M et al (2012) Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg 397:201-207
8. Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130-3136
9. Porpiglia F, Fiori C, Daffara F et al (2010) Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 57:873-878
10. Brix D, Allolio B, Fenske W et al (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609-615
11. Leboulleux S, Deandreis D, Al Ghuzlan A et al (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 162:1147-1153
12. Miller BS, Gauger PG,Hammer GD, DohertyGM(2012) Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomythan after open adrenalectomy. Surgery 152:1150-1157
13. Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667-680
14. Bellantone R, Ferrante A, Boscherini M et al (1997) Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for adrenal cortical carcinoma. Surgery 122:1212-1218
15. Schulick RD, Brennan MF (1999) Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6:719-726
16. Icard P, Goudet P, Charpenay C et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891-897
17. Terzolo M, Berruti A (2008) Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Metab 15:221-226
18. Terzolo M, Angeli A, Fassnacht M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380
19. Huang H, Fojo T (2008) Adjuvant mitotane for adrenocortical cancer - a recurring controversy. J Clin Endocrinol Metab 93:3730-3732
20. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson B (2000) Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11:1281-1287
21. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B (2006) Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501-4504
22. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E (2011) Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 80(5):1477-1484
23. Habra MA, Ejaz S, Feng L et al (2013) A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 98:192-197
24. Berruti A, Fassnacht M, Baudin E et al (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 28:401-402
25. Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115:243-250
26. Beuschlein F, Obracay J, Saeger W et al (2013) Prognostic value of histological markers in localized adrenocortical carcinoma after complete resection. Endocr Rev 34:23-29
27. Stojadinovic A, Ghossein RA, Hoos A et al (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20:941-950
28. Volante M, Bollito E, Sperone P et al (2009) Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 55:535-543
29. Papotti M, Libe R, Duregon E, Volante M, Bertherat J, Tissier F (2011) The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm Cancer 2:333-340
30. Volante M, Sperone P, Bollito E et al (2006) Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 19:1563-1569
31. Fenske W, Volker HU, Adam P et al (2009) Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 16:919-928
32. Duregon E, Volante M, Giorcelli J, Terzolo M, Lalli E, Papotti M (2013) Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol 44:822-828
33. De Reynies A, Assie G, Rickman DS et al (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108-1115
34. Haak HR, Hermans J, van de Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947-951
35. Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392
36. Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96(6):1844-1851
37. Terzolo M, Baudin AE, Ardito A et al (2013) Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 169(3):263-270
38. Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E (2006) Rapidly progressing high o, p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol 64(1):110-113
39. Mauclère-Denost S, Leboulleux S, Borget I et al (2012) High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 166(2):261-268
40. Daffara F, De Francia S, Reimondo G et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15(4):1043-1053
41. D'Avolio A, De Francia S, Basile V et al (2013) Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 23:293-300
42. Chortis V, Taylor AE, Schneider P et al (2013) Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5areductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 98:161-171
43. Zatelli MC, Gentilin E, Daffara F et al (2010) Therapeutic concentrations of mitotane (o, p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 15:2453-2461
44. Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17(3):797-807
45. Assié G, Antoni G, Tissier F et al (2007) Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92(1):148-154
46. Abiven G, Coste J, Groussin L et al (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91(7):2650-2655
47. Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657-666
48. Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T (2003) Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 97(3):554-560
49. Cazejust J, De Baère T, Auperin A et al (2010) Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 21:1527-1532
50. Veytsman I, Nieman L, Fojo T (2009) Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 20(27):4619-4629
51. Fassnacht M, Terzolo M, Allolio B, FIRM-ACT Study Group et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366(23):2189-2197
52. Sperone P, Berruti A, Gorzegno G et al (2006) Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. J Endocrinol Invest 29(6):560-562
53. Sperone P, Ferrero A, Daffara F et al (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17(2):445-453
54. Ferrero A, Sperone P, Ardito A et al (2013) Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. J Endocrinol Invest 36(3):148-152
55. Samnotra V, Vassilopoulou-Sellin R, Fojo AT, Oh WK, LaRocca RV, Ernstoff MS, Memoli VA, Cole BF, Quinn DI, Simmons PA, Tretter CP (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol 25(Suppl 8):15527
56. Quinkler M, Hahner S, Wortmann S et al (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93(6):2057-2062
57. Wortmann S, Quinkler M, Ritter C et al (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 162(2):349-356
58. Berruti A, Sperone P, Ferrero A et al (2012) Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 166(3):451-458
59. Kroiss M, Quinkler M, Johanssen S et al (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, openlabel trial. J Clin Endocrinol Metab 97(10):3495-3503
60. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388
61. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol 75(5):585-591
62. Haluska P, Worden F, Olmos D et al (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65(4):765-773
63. Naing A, Lorusso P, Fu S et al (2013) Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 108(4):826-830
64. Naing A, Kurzrock R, Burger A et al (2011) Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17(18):6052-6060
65. Henley DJ, van Heerden JA, Grant CS, Carney JA, Carpenter PC (1983) Adrenal cortical carcinoma - a continuing challenge. Surgery 94(6):926-931
66. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA (1989) Adrenal cortical carcinoma. Cancer 64(3):765-769
67. Luton JP, Cerdas S, Billaud L et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322(17):1195-1201
68. Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112(6):963-970 (discussion 970-1)
69. Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M (1997) Adrenocortical carcinoma: experience in 45 patients. Oncology 54(6):490-496
70. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88(5):1159-1165
71. Decker RA, Elson P, Hogan TF et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6):1006-1013
72. Van Slooten H, van Oosterom AT (1983) CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 67(4):377-379
73. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67(12):2997-3000
74. Burgess MA, Legha SS, Sellin RV (1993) Chemotherapy with cisplatinum and etoposide (VP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc Am Soc Clin Oncol 12:188 (abstract)
75. Urup T, Pawlak WZ, Petersen PM, Pappot H, Rørth M, Daugaard G (2013) Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. Br J Cancer 108(10):1994-1997
76. Bukowski RM, Wolfe M, Levine HS et al (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11(1):161-165
77. Bonacci R, Gigliotti A, Baudin E et al (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 78(4):546-549
78. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83(10):2194-2200
79. Abraham J, Bakke S, Rutt A et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9):2333-2343